Morgan Stanley Cuts JAZZ Price Target to $314

On October 21, 2026, Morgan Stanley maintained its Overweight rating on Jazz Pharmaceuticals plc (NASDAQ: JAZZ) while lowering its price target from $322.00 to $314.00. The research note outlines the firm's forward-looking view on the biotechnology company as Wall Street firms weigh their positions ahead of upcoming financial updates.

JAZZ Jazz Pharmaceuticals plc

$212.37 ▲ +22.65% year to date

1M 3M YTD

Daily close · Oct 22, 2026

Morgan Stanley's Call on Jazz Pharmaceuticals

In its October 21 note, Morgan Stanley kept its Overweight rating intact while trimming the target by $8.00 from the previous $322.00 level. The firm's target remains well above the recent market price.

Other Institutional Activity in Jazz Pharmaceuticals

Other large funds have also adjusted their holdings in the drugmaker during recent quarters. Franklin Resources, Inc. grew its holdings by 81,297 shares, ending its June 30 quarter with 2,040,250 shares worth about $432,175,950, a 4.2% increase. Meanwhile, LSV Asset Management reduced its stake by 111,705 shares for a 4.7% decrease, finishing with 2,275,145 shares valued at approximately $481,932,582. Fuller & Thaler Asset Management Inc. cut its position by 37,544 shares, a 2.2% drop to 1,638,544 shares worth roughly $347,084,577.

Jazz Pharmaceuticals plc Stock Up 0.2%

Jazz Pharmaceuticals shares recently traded around $212.48 as of October 22, 2026, up about 0.2% from the October 21 close of $211.97. The stock sits below its 50-day moving average of $237.40 and its 52-week high of $266.38, but above its 52-week low of $128.80. The company has a market capitalization of roughly $13.75 billion and trades at a trailing price-to-earnings ratio of 14.52.

Recent Earnings

The biotechnology firm reported trailing twelve-month revenue of $4.60 billion and trailing earnings of $14.59 per share. The company operates with a net profit margin of 20.4% and a return on equity of 22.1%. Its next earnings report is scheduled for November 2, 2026.

Insider Buying and Selling at Jazz Pharmaceuticals plc

Company insiders have made several stock sales in recent months. Chief Executive Officer Renee D. Gala sold 2,000 shares on September 8, 2026, at an average price of $243.03 for a total value of $486,060, and sold another 2,000 shares on October 6, 2026, at $236.40 worth $472,800. Officer Neena M. Patil sold 1,200 shares on September 10, 2026, at $240.94 for a total of $289,128. Director Bruce C. Cozadd sold 6,000 shares on October 1, 2026, at an average price of $230.33, totaling $1,381,980.

Analysts Set New Price Targets

Other Wall Street firms have updated their views on the stock in recent weeks. UBS maintained a Buy rating on September 11, 2026, lifting its price target from $315.00 to $337.00. Citigroup initiated coverage with a Buy rating and a $325.00 target on September 30, 2026. Truist Securities maintained its Buy rating on October 7, 2026, raising its target from $281.00 to $286.00. RBC Capital maintained an Outperform rating on October 8, 2026, moving its target from $299.00 to $296.00.

About Jazz Pharmaceuticals

Headquartered in Dublin, Ireland, Jazz Pharmaceuticals identifies, develops, and commercializes pharmaceutical treatments for patients in the United States, Europe, and international markets. The company focuses on neuroscience and oncology therapeutics.

Bottom Line

Investors will watch the company's upcoming earnings release on November 2, 2026, for further details on revenue growth and product pipeline developments. The stock carries a strong buy recommendation overall from covering analysts.